Eczema drug shows promise in breast cancer trial
NCT ID NCT06637306
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether adding dupilumab (an eczema and asthma drug) to standard immunotherapy and chemotherapy can safely improve outcomes for people with locally advanced triple-negative breast cancer. About 15 participants will receive the combination before surgery. The main goal is to check for severe immune-related side effects, while also measuring how well the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Dupilumab (an eczema/asthma drug) combined with pembrolizumab (immunotherapy) and chemotherapy (paclitaxel and carboplatin)
- What this could lead to
- If successful, this could point toward a new treatment option for triple-negative breast cancer that may improve tumor clearance before surgery.
- What could go wrong
- This is a very early, small pilot trial with only 15 participants, so results may not apply broadly. The drug combination may cause severe immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mount Sinai Health System
RECRUITINGNew York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Gene-Edited immune cells tame Hard-to-Treat cancers?
- Can a One-Time Anti-Inflammatory shot during surgery curb Triple-Negative breast Cancer's return?
- Triple-Drug cocktail aims to stall aggressive breast cancer
- Could a vaccine stop Triple-Negative breast cancer from coming back?
- Engineered immune cells take aim at Mesothelin-Positive tumors
- New imaging tracer could spot hidden cancers